Berenberg Initiates Coverage On Arcosa with Buy Rating, Announces Price Target of $63
Berenberg analyst Daniel Wang initiates coverage on Arcosa (NYSE:ACA) with a Buy rating and announces Price Target of $63.
Return on Capital Employed Overview: Arcosa
After pulling data from Benzinga Pro it seems like during Q2, Arcosa (NYSE:ACA) earned $31.30 million, a 36.68% increase from the preceding quarter. Arcosa also posted a total of $515.10 million in sales, a 16.96% increase since Q1.
Arcosa Q2 Adj. EPS $0.60 Beats $0.57 Estimate, Sales $515.10M Beat $491.65M Estimate; Reaffirms FY21 Adj. EBITDA $270M-$290M
Arcosa (NYSE:ACA) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.57 by 5.26 percent. This is a 17.81 percent decrease over earnings of $0.73 per share from the same period
Arcosa Q2 Adj. EPS $0.60 Beats $0.57 Estimate, Sales $515.10M Beat $491.65M Estimate
Arcosa (NYSE:ACA) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.57 by 5.26 percent. This is a 17.81 percent decrease over earnings of $0.73 per share from the same period
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
Sidoti & Co. Upgrades Arcosa to Buy, Announces $66 Price Target
Sidoti & Co. analyst Julio Romero upgrades Arcosa (NYSE:ACA) from Neutral to Buy and announces $66 price target.